Roth Capital started coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report released on Thursday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $77.00 price objective on the biotechnology company’s stock.
Other analysts also recently issued reports about the stock. ValuEngine downgraded shares of Arcturus Therapeutics from a buy rating to a hold rating in a report on Thursday, July 2nd. HC Wainwright raised their target price on shares of Arcturus Therapeutics from $62.00 to $78.00 and gave the stock a buy rating in a report on Friday, July 24th. WBB Securities downgraded shares of Arcturus Therapeutics from a buy rating to a hold rating and set a $31.00 price objective on the stock. in a report on Tuesday, June 9th. B. Riley initiated coverage on shares of Arcturus Therapeutics in a report on Sunday, July 12th. They issued a buy rating and a $70.00 price objective on the stock. Finally, Zacks Investment Research downgraded shares of Arcturus Therapeutics from a buy rating to a hold rating in a report on Monday, July 20th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Arcturus Therapeutics currently has an average rating of Buy and an average price target of $50.44.
Shares of ARCT stock opened at $52.23 on Thursday. The company’s 50 day moving average price is $47.94 and its two-hundred day moving average price is $28.54. Arcturus Therapeutics has a 52 week low of $8.51 and a 52 week high of $63.45.
Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $2.65 million for the quarter, compared to analyst estimates of $7.52 million. Arcturus Therapeutics had a negative return on equity of 409.05% and a negative net margin of 151.34%. On average, analysts forecast that Arcturus Therapeutics will post -2.56 EPS for the current year.
In other news, CFO Andy Sassine bought 5,000 shares of the stock in a transaction that occurred on Wednesday, June 10th. The shares were acquired at an average cost of $29.74 per share, for a total transaction of $148,700.00. Following the completion of the acquisition, the chief financial officer now owns 273,245 shares in the company, valued at $8,126,306.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Joseph E. Payne bought 1,000 shares of the stock in a transaction that occurred on Wednesday, June 10th. The shares were purchased at an average price of $31.69 per share, for a total transaction of $31,690.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 6,450 shares of company stock worth $195,389. 19.20% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its position in Arcturus Therapeutics by 19.5% during the first quarter. BlackRock Inc. now owns 75,424 shares of the biotechnology company’s stock worth $1,026,000 after purchasing an additional 12,330 shares during the period. Engineers Gate Manager LP bought a new position in Arcturus Therapeutics during the first quarter worth $305,000. Morgan Stanley boosted its position in Arcturus Therapeutics by 27.4% during the first quarter. Morgan Stanley now owns 202,239 shares of the biotechnology company’s stock worth $2,749,000 after purchasing an additional 43,497 shares during the period. Geode Capital Management LLC boosted its position in Arcturus Therapeutics by 4.7% during the first quarter. Geode Capital Management LLC now owns 88,487 shares of the biotechnology company’s stock worth $1,201,000 after purchasing an additional 3,992 shares during the period. Finally, Credit Suisse AG bought a new position in Arcturus Therapeutics during the fourth quarter worth $641,000. Institutional investors and hedge funds own 23.81% of the company’s stock.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.
See Also: Dividend Achievers
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.